How many drugs treat Chronic heart failure?

Drug Landscape tracks 10 marketed treatments for Chronic heart failure (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Chronic heart failure?

Most recent: Diovan — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-heart-failure.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic heart failure — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic heart failure (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic heart failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Verquvo	VERICIGUAT	Merck & Co.	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	2021-01-01
Corlanor	IVABRADINE	Amgen	Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	2015-01-01
Farxiga	DAPAGLIFLOZIN	AstraZeneca	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Atacand	CANDESARTAN CILEXETIL	ANI Pharmaceuticals	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1998-01-01
Diovan	VALSARTAN	Novartis	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1996-01-01
Coreg	CARVEDILOL	Waylis	alpha-Adrenergic Blocker [EPC]	Beta-2 adrenergic receptor	1995-01-01
Accupril	QUINAPRIL	Pfizer	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Altace	RAMIPRIL	King Pfizer	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01
Zestril	lisinopril	Generic (originally Merck/AstraZeneca)	Thiazide Diuretic [EPC]	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1987-12-29

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-21 — Diovan · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 3 drugs in Chronic heart failure
AstraZeneca · 2 drugs in Chronic heart failure
ANI Pharmaceuticals · 1 drug in Chronic heart failure
Amgen · 1 drug in Chronic heart failure
Generic (originally Burroughs Wellcome/GSK) · 1 drug in Chronic heart failure
AstraZeneca Turkey · 1 drug in Chronic heart failure
Bayer · 1 drug in Chronic heart failure
Astrazeneca Ab · 1 drug in Chronic heart failure
Aarxion Anda Hlding · 1 drug in Chronic heart failure
Dr. Reddy's Laboratories Limited · 1 drug in Chronic heart failure
ACS Biomarker · 1 drug in Chronic heart failure
· 1 drug in Chronic heart failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic heart failure:

Cite this brief

Drug Landscape (2026). Chronic heart failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-heart-failure. Accessed 2026-06-10.

Chronic heart failure full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing